AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03952650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Phosphate
Description: Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.
Study NCT02057835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751 low dose 2
Description: BI 691751 low dose 2
Study NCT04889014 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Personal genomic educational testing (PGET)
Description: PGET consisted of a panel of pharmacogenomic variants
Study NCT04889014 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: No personal genomic educational testing (NPGET)
Description: Lack of pharmacogenomic testing
Study NCT03528187 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: MRI scan (not involving ionising radiation)~The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
Study NCT03528187 — intervention group
Intervention type: OTHER
Intervention: Written Consent
Description: Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.
Study NCT03556618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Person Care (WPC) Reentry Program - Pre & Post Release services
Description: Social network intervention to provide care coordination and social support during youth reentry before release and post-release from jail.
Study NCT03952650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine Phosphate
Description: Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.
Study NCT03952650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: PfSPZ Challenge (NF54) acts as the immunogen in the PfSPZ-CVac approach to vaccinating against malaria. Participants will receive either one (in the pilot phase) or 3 (in the main phase) 400,000 or 300,000 aseptic, purified, cryopreserved, fully infectious PfSPZ injections by DVI (with concurrent administration of antimalarial drugs). Following immunization, participants in the main phase will be followed through the transmission season in order to assess vaccine efficacy.
Study NCT00912444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide
Description: Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles
Study NCT00912444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, cyclophosphamide
Description: Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles
Study NCT03952650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses.
Study NCT00416949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-specific dosimetry
Description: Patient-specific 3D-RD dosimetry was applied to the data collected
Study NCT01011296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: Single 0.2mg dose of intravenous infusion
Study NCT01011296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: Single 1mg dose of intravenous infusion
Study NCT01011296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: Single 3 mg dose of intravenous infusion
Study NCT00038415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLL vaccine using DNA plasmid vector
Study NCT02117154 — intervention group
Intervention type: DEVICE
Intervention: 6-day Continuous Glucose Monitoring System
Description: performed 3 times on a patient, one month apart
Study NCT04574505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eufortyn Colesterolo Plus
Description: Food supplement combination containing bergamot (Vazguard®) phytosomal polyphenolic fraction associated with standardized artichoke extract (Pycrinil®, Cynara Cardunculus L) and Cynara scolimus, associated with high coenzyme Q10 bioavailability(Q10 phytosome® Ubiqsome) and zinc.
Study NCT04574505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02015936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Six Week Physical Activity Intervention
Description: Tailored Wii Fit prescription based on physical fitness assessments and a schedule of six home visits by an oncology RN.
Study NCT02015936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progress Reporting
Description: Participants will keep a log to record the physical activities they have done with the Wii Fit during the 6-week period. Audio-recording may be included for quality control. Self-report data will be collected by Internet surveys through the University of South Florida (USF) Health Qualtrics application at baseline (T1) and at 6 weeks post-intervention (T2). The nurse will take small amount of the participant's hair (20 strands) for a hormone test during the first visit and last visit.
Study NCT06737263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioHPP abutment
Description: Patients in the test group receive abutments made of BioHPP
Study NCT06737263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium abutment
Description: Patients in the control group receive abutments made of titanium
Study NCT06737263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zirconia abutment
Description: Patients in the control group receive abutments made of zirconia
Study NCT00875459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject™
Description: Subcutaneous injection 25 IU/mL
Study NCT00406237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline
Description: Single intravenous dose of tigecycline 50 mg, as a 30-minute infusion
Study NCT03281720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAD
Description: the same intervention as listed in the arm description
Study NCT03514537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcannula harvest adipose stromal tissues
Description: Use of disposable, closed syringe microcannula harvest autologous adipose stroma and stem/stromal cells
Study NCT03514537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centricyte 1000
Description: Centricyte 1000, closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
Study NCT03514537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sterile Normal Saline IV Deployment of cSVF
Description: Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery including 150 micron in-line filtration
Study NCT03514537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liberase
Description: Liberase TM for use to enzymatically isolate cellular stromal vascular fraction
Study NCT03514537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Sterile, Normal Saline 500 for Intravenous use
Study NCT03555344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mantra Chikitsa
Description: Specific Mantra were given to chants for 15 mins and resting in the impact of chants for following 15 mins.
Study NCT04405388 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo will be given orally as capsule (same size and weight as Spermidine capula)
Study NCT04405388 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Spermidine
Description: Spermidine will be given orally as capsule (4mg/day)
Study NCT01178411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Tivantinib 360 mg (3 x 120 mg tablets or capsules) twice daily by mouth.
Study NCT01178411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Cancer Combination Therapy
Description: Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the same dose and schedule in which they were administered in the original (previous) study.
Study NCT04981561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-251
Description: Single dose of GATE-251
Study NCT04981561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05017636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shock wave therapy
Description: The participants received the treatment protocol established by the manufacturer of the Thork Shock Wave® device, IBRAMED- Industria Brasileira de Equipamentos Electromédicos, Amparo, São Paulo approved by Anvisa No. 10360310036. (Figure 1). The parameters were, 4,000 thousand shots with energy of 180mJ and frequency of 15Hz with 15mm stainless steel tip and 2,000 shots with energy of 100mJ and frequency of 15Hz with 15mm plastic tip, and for the tip slip, Neutral Thork® Lotion, RMC was used. Seven ESWT sessions were held, the average time of each was seven minutes, twice a week and the seventh session was held minutes before the surgical procedure of bariatric surgery, therapy was performed in an area of 150cm² on the left side of the abdominal region following the midline. The right side of the participants' abdomen did not receive ESWT and was termed as control.
Study NCT02887586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular needling
Description: Patients will be treated with auricular needling for 4 weeks. 4-8 specific auricular acupoints are selected unilaterally at a time, and alternate to another side every 2-3 days, treatment will last for 4 consecutive weeks. The following 4 ear acupoints points will be selected for every patient: Ear Shenmen, Stoma, Spleen, and Subcortex. Other ear acupoints including Triple Energizer, Liver, Sympathetic Nerve and Smallintestine will be selected based on the condition of patients. Treatment will be performed by a registered Chinese medicine practitioner.
Study NCT03952650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pyrimethamine
Description: Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses.
Study NCT04256031 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: The structured questionnaire, Visual Analogue Scale, Copenhagen Neck Functional Disability Scale, Shoulder Disability Questionnaire, World Health Organization Quality of Life Instrument-Short Form, and Smartphone Addiction Scale-Short Version will be applied to all participants respectively. Lastly, posture analysis will be performed to all participants by using the New York Posture Rating Chart.
Study NCT06021444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DKM420
Description: A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
Study NCT06021444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conjuran
Description: A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
Study NCT00552838 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Academic Detailing by the Antimicrobial Utilization Team (AUT)
Description: Physicians caring for patients who were prescribed one of three antimicrobials were randomly assigned to academic detailing by the AUT. The AUT would review the antimicrobial prescription and provide consultation to the ordering physician if the prescription is appropriate and provide feedback on a better alternative if inappropriate.
Study NCT04358562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
Study NCT04358562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
Study NCT02345343 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Study NCT00145327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
Study NCT00145327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL physiologic 0.9% normal saline for intravenous infusion.
Study NCT01283386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: 10 mg/m\^2 orally on Days 1-7 of each 28-day cycle for 6 cycles
Study NCT01283386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 150 mg/m\^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles
Study NCT01283386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 20 mg/m\^2 IV or 32 mg/m2 orally Days 1-3 of each 28-day cycle for 6 cycles
Study NCT01283386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)
Study NCT01283386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)
Study NCT04027946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: Participants will receive LMB-100 on days 1, 3 and 5 of a 21-day cycle for up to 2 cycles.
Study NCT04027946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Participants will receive pembrolizumab on day 1 of each subsequent 21-day cycle.
Study NCT04027946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mesothelin Expression
Description: Testing for mesothelin expression performed at screening
Study NCT04027946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TrueSight Oncology 500
Description: Testing for ROS oncogene 1 (ROS1) gene, anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) variations performed at screening.
Study NCT01320098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Parenting Program
Description: The Home-Based Parenting Program aims to improve impulsive and oppositional behaviors in 3 and 4 year-olds. The program involves 8 home visits with a therapist. The visits focus on the skills listed below as a means of improving your child's behavior.~1. Helping you set developmentally appropriate goals for your child. One way we do this is by focusing on situations that occur naturally in your home. Another way is by having you engage in activities with your child that focus on improving attention and the ability to delay.~2. Increasing the quality and quantity of positive interactions between you and your child~3. Changing the way you respond to your child's inappropriate behaviors so as to reduce the frequency of negative interactions.~4. Improving your parenting skills. This program also includes between-session homework tasks so that you can practice the skills you have learned throughout the week.
Study NCT01320098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-Based Parenting Program
Description: The Clinic-Based Parenting Program aims to improve ADHD symptoms by reducing noncompliance, which is common in children with ADHD. Parents learn how to help their child attend to and comply with requests and directions so as to improve compliance and attention.~The program involves 8 clinic visits with a therapist. Parents learn various parenting skills to help improve their child's behaviors.~Parents learn techniques and skills to promote positive interactions with their child, including:~1. Increasing the positive attention you give to your child.~2. Reducing the inappropriate use of commands, questions and criticisms.~3. Appropriate use of praise and physical attention (e.g., hugs) as rewards.~4. Actively ignoring minor, inappropriate behaviors. Parents also learn how to: increase compliance via clear instruction; respond to compliant and noncompliant behaviors; and create and use clear rules about appropriate and inappropriate child behaviors.
Study NCT01320098 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-List Control Group
Description: If your child is randomized to the 8-week Wait-List group, you and your child will be asked to attend 2 assessment visits -1 screening/baseline visit and one 8 weeks later. These assessment visits will take place at our clinic. After completing the second assessment, you will receive your choice of either the home-based or clinic-based parenting program.
Study NCT02458300 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nebulization of hypertonic saline
Description: application of hypertonic saline serum through a mask fogging or a box fogging
Study NCT02458300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulization of hypertonic saline
Description: application of hypertonic saline serum through a mask fogging or a box fogging
Study NCT02458300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged slow expiration technique (PSE)
Description: Passive expiratory aid implemented baby. the child is placed supine on a hard surface. Thoracoabdominal slow manual pressure that begins at the end of a spontaneous and continuous exhalation to residual volume is exercised. Oppose reaches 2 or 3 breaths. Vibrations can accompany the art. The goal is to achieve a greater expiratory volume.
Study NCT02458300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient coughing Provocation (TP)
Description: Tp is based on the mechanism reflects cough induced by stimulation of the buttons on the wall of the trachea extrathoracic mechanoreceptors. The child is placed supine. A short pressure is done with the thumb on the tracheal conduit (in the sternal notch) at the end of inspiration, or at the beginning of expiration. With the other hand holding the abdominal region we prevent the dissipation of energy and make the explosion tussive more effective. It is done after the PSE.
Study NCT02458300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inspiratory maneuver to rhinopharyngeal cleaning DRR
Description: After the inspiratory reflection following the PSE, the TP or crying. At the end of expiratory time the child's mouth is closed with the back of his hand just finished his chest support, raising the jaw and forcing the child to an inspiration with the nose
Study NCT02458300 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aspiration of secretions
Description: Suctioning with a probe by a vacuum system installed on the wall.
Study NCT02458300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration of secretions
Description: Suctioning with a probe by a vacuum system installed on the wall.
Study NCT00894920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: biotin
Description: capsule approximately 30 mcg daily 21 days
Study NCT00894920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: biotin
Description: capsule 300 mcg daily 21 days
Study NCT01801527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation group
Description: Interventions will be based on to provide cardiovascular, mobility, strength and stretching exercises through telerehabilitation system
Study NCT02205138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLOB® cells with ceramic scaffold
Description: Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia